High-throughput screening (HTS) has been one of the most productive engines in drug discovery for decades. The ability to test hundreds of thousands of compounds against a biological target in days rather than years transformed early-stage programs and made large compound library screening a realistic component of discovery strategy. The logic driving that investment has always been straightforward: more compounds tested means more chances to find a hit.
What has changed is the nature of the assays doing the testing. First-generation HTS was built around relatively simple biochemical measurements — enzyme activity, binding displacement, reporter gene expression — where signal generation was robust and the readout was clean. The push toward more physiologically relevant models has made the biology considerably richer, but it has also made the data considerably harder to generate reliably. A 2024 review in Bioengineering and Translational Medicine on high-throughput cell culture technologies described the tension directly: high-throughput systems require uniformity, assay miniaturization, specific target identification, and process simplification — requirements that pull in different directions as biological complexity increases.
The result is a field working through a data quality problem that throughput alone does not solve. Getting more data faster only creates value if the data is reliable enough to make decisions from.
The tension between complexity and scale
Functional biology assays, those measuring the activity of signaling pathways, cellular responses to drug treatment, or the behavior of more physiologically relevant cell models, generate richer information than simple biochemical measurements. They capture emergent biology that single-target assays miss. They are also more sensitive to the sources of variability that high-throughput formats introduce.
Reagent stability is one of the most common points of failure. Enzymes, cell lines, reporter systems, and detection reagents must all remain consistent across the full duration of a screening campaign, which can span days or weeks across thousands of plates. Drift in any component produces systematic error that is difficult to distinguish from real biological signal after the fact. The same review noted that assay formats without wash steps, such as homogeneous or additive tests, reduce one major source of variability, but the fundamental challenge of maintaining signal stability across a large-scale run remains.
Plate-to-plate and day-to-day variability are related problems. Even well-validated assays can show performance differences between batches of reagents, cell passage numbers, or ambient environmental conditions. In a primary screen, those differences introduce noise. In a comparative analysis across a large compound library, they can shift rank-ordering in ways that move real hits out of the selection window and push artifacts in.
The standard quantitative metric for assay performance in HTS is the Z-prime factor, which captures the separation between positive and negative controls relative to their variability. A Z-prime above 0.5 is the conventional threshold for a screenable assay. But Z-prime is calculated from controls, not from the compounds themselves, and an assay that passes the Z-prime threshold on control plates can still produce noisy data across the compound set if the detection chemistry is sensitive to compound interference or if signal stability degrades over the course of a long run.
Where assay chemistry determines what is possible
The chemistry underlying signal generation is increasingly recognized as a primary determinant of assay performance in complex formats, and one of the most tractable levers for improving data quality without sacrificing throughput.
Detection methods differ substantially in their sensitivity to interference. Fluorescence intensity-based assays are broadly applicable but prone to compound autofluorescence and inner filter effects, particularly when screening libraries with high chemical diversity. Time-resolved fluorescence and fluorescence resonance energy transfer (FRET)-based formats reduce those interference effects by adding a temporal or spectral selectivity dimension. Homogeneous time-resolved FRET (HTRF) and bioluminescence-based detection platforms have gained significant adoption in HTS specifically because their signal-to-background ratios are more robust to the kind of compound interference that degrades assay reliability across large and diverse libraries.
Multiplexed formats add another layer of complexity. The ability to measure multiple analytes from a single well is scientifically attractive — it reduces sample consumption, captures pathway relationships that single-readout assays miss, and can help distinguish on-target effects from cytotoxicity within a single experiment. A 2025 paper in Current Protocols on high-throughput protein expression and assay approaches emphasized that scalable workflows achieving reliable functional measurements depend on careful matching of detection format to the specific biological question being asked — not on applying a single detection chemistry universally.
In multiplexed formats, that matching becomes more demanding. Spectral overlap between fluorescent labels, differential stability of multiple detection reagents, and the additive potential for compound interference across multiple channels all require deliberate assay design choices rather than default selections.
Noise, artifacts, and the hit identification problem
In primary screening, noise is manageable: Z-prime thresholds, robust statistics, and confirmation screens are all designed to filter artifacts. The more consequential problem emerges in comparative analysis across large compound libraries, where the goal is rank-ordering compounds by activity or identifying structure-activity relationships from screening data.
Those analyses depend on the assumption that the signal variation observed across a plate or a run reflects biological differences between compounds rather than technical differences in how the assay performed at different positions, time points, or reagent batches. When that assumption does not hold, the rank-ordering is wrong in ways that are difficult to detect from the data alone, especially when the effect is systematic and not necessarily random.
Edge effects are a well-known, and documented example. Wells at the perimeter of high-density plates often show different evaporation rates, temperature gradients, or liquid handling behavior than interior wells, producing systematic signal differences that track position rather than biology. In 384-well formats, edge effects are manageable. In 1536-well formats, they require more careful mitigation through plate design, environmental control, and data normalization.
The practical implication is that the data quality problem in HTS is not primarily a statistical problem, normalization and robust statistics can correct for known sources of variation. It is a scientific problem: The goal is to build assays in which the biology is the dominant source of signal variation, so that compound comparisons reflect genuine differences in activity rather than differences in how the assay behaved.
What reliable screening actually requires
The field has learned a set of practical principles from decades of HTS experience, and they are as relevant to next-generation functional assays as they were to first-generation biochemical screens.
Assay validation before scaling is the most important. An assay that has not been systematically evaluated for variability, signal stability, DMSO tolerance, and compound interference is not ready for a large campaign regardless of its biological interest. Validation under conditions that match actual screening conditions — plate density, detection format, liquid handling system, throughput rate — reveals problems that small-scale development misses.
Miniaturization and assay chemistry should be co-developed. Moving from 96-well to 384-well or 1536-well formats changes the physics of liquid handling, evaporation, and detection in ways that affect assay performance. Assay chemistry validated in one format must be re-evaluated in the miniaturized format before committing to a large campaign.
Quality metrics should track the compound data, not just the controls. Z-prime and signal-to-background ratios characterize assay performance at the control level. Systematic tracking of hit rates, confirmed hit rates, and structure-activity relationships across the compound data provides a more complete picture of whether the screen is generating reliable biological information or primarily generating technical artifacts.
The deeper principle connecting all of these is straightforward: throughput is a means, not an end. The value of a screening campaign is determined by the quality of the biological information it generates and the decisions that information supports. An assay that generates a million data points but cannot reliably rank-order compounds by activity has not delivered a screening campaign — it has delivered a noise floor.
For discovery teams investing in functional biology assays, the question worth prioritizing is not how many compounds the platform can test per day, but how reliably the assay can detect real biological signal across the full range of structural diversity in the library. The answer to that question starts with assay design and detection chemistry, and it shapes everything downstream.
